Home > Organization > Divisions and Independent Research Units > Division of Cancer Therapeutics > Publications
Publications
External Profiles
Visit our profiles for the most up-to-date publication lists and citation metrics.
Google Scholar PubMed ORCIDSelected Publications
Targeting Chromatin Remodeling Deficiencies & Synthetic Lethality
- Saito R, Fukushima M, Sasaki M, Okamoto A, Ogiwara H*.
Targeting USP8 Causes Synthetic Lethality through Degradation of FGFR2 in ARID1A-Deficient Ovarian Clear Cell Carcinoma.
NPJ Precis Oncol. 2025;9(1):69. [Publication] - Sasaki M, Kato D, Yoshida H, Shimizu T, Ogiwara H*.
Efficacy of CBP/p300 Dual Inhibitors against De-repression of KREMEN2 in cBAF-Deficient Cancers.
Cancer Res Commun. 2025;5(1):24-38. [Publication] - Sasaki M, Kato D, Murakami K, Yoshida H, Takase S, Otsubo T, Ogiwara H*.
Targeting dependency on a paralog pair of CBP/p300 against de-repression of KREMEN2 in SMARCB1-deficient cancers.
Nat Commun. 2024;15(1):4770. [Publication] - Sasaki M, Ogiwara H*.
Efficacy of glutathione inhibitor eprenetapopt against the vulnerability of glutathione metabolism in SMARCA4-, SMARCB1- and PBRM1-deficient cancer cells.
Sci Rep. 2024;14(1):31321. [Publication] - Ogiwara H*., Takahashi K., Sasaki M., Kuroda T., Yoshida H., Watanabe R., Maruyama A., Makinoshima H., Chiwaki F., Sasaki H., Kato T., Okamoto A., Kohno T*.
Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers.
Cancer Cell. 2019;35(2):177-190.e8. [Publication]
Full List by Year
＜2025＞
Saito R#, Fukushima M#, Sasaki M, Okamoto A, Ogiwara H*
Targeting USP8 Causes Synthetic Lethality through Degradation of FGFR2 in ARID1A-Deficient Ovarian Clear Cell Carcinoma
NPJ Precis Oncol. 9(1):69. 2025
doi: 10.1038/s41698-025-00850-8. PMID: 40074856
Sasaki M, Kato D, Yoshida H, Shimizu T, Ogiwara H*.
Efficacy of CBP/p300 Dual Inhibitors against De-repression of KREMEN2 in cBAF-Deficient Cancers.
Cancer Res Commun. 5(1):24-38. 2025
doi: 10.1158/2767-9764.CRC-24-0484. PMID: 39625239
＜2024＞
Sasaki M, Kato D, Murakami K, Yoshida H, Takase S, Otsubo T, Ogiwara H*.
Targeting dependency on a paralog pair of CBP/p300 against de-repression of KREMEN2 in SMARCB1-deficient cancers.
Nat Commun. 15(1):4770. 2024
doi: 10.1038/s41467-024-49063-w. PMID: 38839769
Sasaki M and Ogiwara H*.
Efficacy of glutathione inhibitor eprenetapopt against the vulnerability of glutathione metabolism in SMARCA4-, SMARCB1- and PBRM1-deficient cancer cells.
Sci Rep. 14(1):31321. 2024
doi: 10.1038/s41598-024-82753-5. PMID: 39732845
＜2023＞
Kanada R*, Kagoshima Y, Suzuki T, Nakamura A, Funami H, Watanabe J, Asano M, Takahashi M, Ubukata O, Suzuki K, Aikawa T, Sato K, Goto M, Setsu G, Ito K, Kihara K, Kuroha M, Kohno T, Ogiwara H, Isoyama T, Tominaga Y, Higuchi S, Naito H.
Discovery of DS-9300: A Highly Potent, Selective, and Once-Daily Oral EP300/CBP Histone Acetyltransferase Inhibitor. J Med Chem. 66(1):695-715. 2023
doi: 10.1021/acs.jmedchem.2c01641. PMID: 36572866.
＜2022＞
Kobayashi Y*, Takeda T, Kunitomi H, Chiwaki F, Komatsu M, Nagai S, Nogami Y, Tsuji K, Masuda K, Ogiwara H, Sasaki H, Banno K, Aoki D.
Response Predictive Markers and Synergistic Agents for Drug Repositioning of Statins in Ovarian Cancer.
Pharmaceuticals. 15(2):124. 2022
doi: 10.3390/ph15020124. PMID: 35215239
＜2020＞
Sasaki M and Ogiwara H*.
Synthetic Lethal Therapy Based on Targeting the Vulnerability of SWI/SNF Chromatin Remodeling Complex-Deficient Cancers.
Cancer Science. 111(3):774‐782. 2020 (Review Article)
doi: 10.1111/cas.14311. PMID: 31955490
Sasaki M, Chiwaki F, Kuroda T, Komatsu M, Matsusaki K, Kohno T, Sasaki H, Ogiwara H*.
Efficacy of Glutathione Inhibitors for the Treatment of ARID1A-Deficient Diffuse-Type Gastric Cancers.
Biochem. Biophys. Res. Commun. 522(2): 342-347. 2020
doi: 10.1016/j.bbrc.2019.11.078. PMID: 31761322.
＜2019＞
Ogiwara H*., Takahashi K., Sasaki M., Kuroda T., Yoshida H., Watanabe R., Maruyama A., Makinoshima H., Chiwaki F., Sasaki H., Kato T., Okamoto A., Kohno T*.
Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers.
Cancer Cell. 35(2):177-190.e8. 2019
doi: 10.1016/j.ccell.2018.12.009 PMID: 30686770
Kuroda T, Ogiwara H*, Sasaki M, Tahahashi K, Yoshida H, Kiyokawa T, Sudo K, Tamura K, Kato T, Okamoto A, Kohno T.
Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.
Gynecol Oncol. 155(3):489-498. 2019
doi: 10.1016/j.ygyno.2019.10.002 PMID: 31604667
＜~2018＞
Kanke Y, Shimomura A, Saito M, Honda T, Shiraishi K, Shimada Y, Watanabe R, Yoshida H, Yoshida M, Shimizu C, Takahashi K, Totsuka H, Ogiwara H, Hirose S, Kono K, Tamura K, Okamoto A, Kinoshita T, Kato T, Kohno T.
Gene aberration profile of tumors of adolescent and young adult females.
Oncotarget. 9(5):6228-6237. 2017
doi: 10.18632/oncotarget.23765. PMID: 29464067
Ogiwara H., Sasaki M., Mitachi T., Oike T., Higuchi S., Tominaga Y., Kohno T.
Targeting p300 addiction in CBP-deficient cancers causes synthetic lethality via apoptotic cell death due to abrogation of MYC expression
Cancer Discov. 6(4): 430-445. 2016
doi: 10.1158/2159-8290.CD-15-0754. PMID: 26603525
Alagoz M, Katsuki Y, Ogiwara H, Ogi T, Shibata A, Kakarougkas A, Jeggo P.
SETDB1, HP1 and SUV39 promote repositioning of 53BP1 to extend resection during homologous recombination in G2 cells.
Nucleic Acids Res. 43(16):7931-7944. 2015
doi: 10.1093/nar/gkv722. PMID: 26206670
Amornwichet N, Oike T, Shibata A, Nirodi CS, Ogiwara H, Makino H, Kimura Y, Hirota Y, Isono M, Yoshida Y, Ohno T, Kohno T, Nakano T.
The EGFR mutation status affects the relative biological effectiveness of carbon-ion beams in non-small cell lung carcinoma cells.
Sci Rep. 5: 11305. 2015
doi: 10.1038/srep11305. PMID: 26065573
Oike T., Ogiwara H., Amornwichet N., Nakano T., Kohno T.
Chromatin-regulating proteins as targets for cancer therapy.
J Radiat Res. 55(4):613-628. 2014
doi: 10.1093/jrr/rrt227. PMID: 24522270
Oike T., Ogiwara H., Nakano T., Kohno T.
Proposal for a synthetic lethality therapy using the paralog dependence of cancer cells--response.
Cancer Res. 74(17):4948-4949. 2014
doi: 10.1158/0008-5472.CAN-14-0674. PMID: 25136072
Oike T., Komachi M., Ogiwara H., Amornwichet N., Saitoh Y., Torikai K., Kubo N., Nakano T., Kohno, T.
C646, a selective small molecule inhibitor of histone acetyltransferase p300, radiosensitizes lung cancer cells by enhancing mitotic catastrophe.
Radiother Oncol. 111(2): 222-227. 2014.
doi: 10.1016/j.radonc.2014.03.015. PMID: 24746574
Watanabe R., Ui A., Kanno S., Ogiwara H., Nagase T., Kohno T., Yasui A.
SWI/SNF factors required for cellular resistance to DNA damage include ARID1A and ARID1B and show interdependent protein stability.
Cancer Res. 74(9):2465-2475. 2014
doi: 10.1158/0008-5472.CAN-13-3608. PMID: 24788099
Kato K., Nakajima K., Ui A., Muto-Terao Y., Ogiwara H., Nakada S.
Fine-tuning of DNA damage-dependent ubiquitination by OTUB2 supports the DNA repair pathway choice.
Mol Cell 53(4):617-630. 2014
doi: 10.1016/j.molcel.2014.01.030. PMID: 24560272
Nakaoku T, Tsuta K, Ichikawa H, Shiraishi K, Sakamoto H, Enari M, Furuta K, Shimada Y, Ogiwara H, Watanabe S, Nokihara H, Yasuda K, Hiramoto M, Nammo T, Ishigame T, Schetter AJ, Okayama H, Harris CC, Kim YH, Mishima M, Yokota J, Yoshida T, Kohno T.
Druggable oncogene fusions in invasive mucinous lung adenocarcinoma.
Clin Cancer Res. 20(12): 3087-3093. 2014
doi: 10.1158/1078-0432.CCR-14-0107. PMID: 24727320
Amornwichet N, Oike T, Shibata A, Ogiwara H, Tsuchiya N, Yamauchi M, Saitoh Y, Sekine R, Isono M, Yoshida Y, Ohno T, Kohno T, Nakano T.
Carbon-ion beam irradiation kills X-ray-resistant p53-null cancer cells by inducing mitotic catastrophe.
PLoS One. 9(12):e115121. 2014
doi: 10.1371/journal.pone.0115121. PMID: 25531293
Mizukami T., Shiraishi K., Shimada Y., Ogiwara H., Tsuta K., Ichikawa H., Sakamoto H., Kato M., Shibata T., Nakano T., Kohno, T.
Molecular mechanisms underlying oncogenic RET fusion in lung adenocarcinoma.
J Thorac Oncol. 9(5):622-630. 2014
doi: 10.1097/JTO.0000000000000135. PMID: 24722152
Ui A., Ogiwara H., Nakajima S., Kanno S., Watanabe R., Harata M., Okayama H., Harris C. C., Yokota J., Yasui A., Kohno, T.
Possible involvement of LKB1-AMPK signaling in non-homologous end joining.
Oncogene. 33(13):1640-1648. 2014
doi: 10.1038/onc.2013.125. PMID: 23584481
Oike T., Ogiwara H., Tominaga Y., Ito K., Ando O., Tsuta K., Mizukami T., Shimada Y., Isomura H., Komachi M., Kohno T.
A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1.
Cancer Res. 73(17):5508-5518. 2013
doi: 10.1158/0008-5472.CAN-12-4593 PMID: 23872584
Ogiwara H., Ui A., Shiotani B., Zou L., Yasui A., Kohno, T.
Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
Carcinogenesis. 34(11):2486-2497. 2013
doi: 10.1093/carcin/bgt240 PMID: 23825154
Oike T., Ogiwara H., Nakano T., Yokota J., Kohno T.
Inactivating mutations in SWI/SNF chromatin remodeling genes in human cancer.
Jpn J Clin Oncol. 43(9):849-855. 2013
doi: 10.1093/jjco/hyt101. PMID: 23904343
Ogiwara H., and Kohno T.
CBP and p300 histone acetyltransferases contribute to homologous recombination by transcriptionally activating the BRCA1 and RAD51 genes.
PLoS One. 7(12):e52810. 2012
doi: 10.1371/journal.pone.0052810. PMID: 23285190
Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T, Sakamoto H, Tsuta K, Furuta K, Shimada Y, Iwakawa R, Ogiwara H, Oike T, Enari M, Schetter AJ, Okayama H, Haugen A, Skaug V, Chiku S, Yamanaka I, Arai Y, Watanabe S, Sekine I, Ogawa S, Harris CC, Tsuda H, Yoshida T, Yokota J, Shibata T.
KIF5B-RET fusions in lung adenocarcinoma.
Nat Med. 18(3):375-357. 2012
doi: 10.1038/nm.2644. PMID: 22327624
Oike T., Ogiwara H., Torikai K.,Nakano T., Yokota J., Kohno T.
Garcinol, a histone acetyltransferase inhibitor, radiosensitizes cancer cells by inhibiting non-homologous end joining.
Int J Radiat Oncol Biol Phys. 84(3):815-821. 2012
doi: 10.1016/j.ijrobp.2012.01.017. PMID: 22417805
Ogiwara H., Ui A., Otsuka A., Satoh H., Yokomi I., Nakajima S., Yasui A., Yokota J., Kohno, T.
Histone acetylation by CBP and p300 at double-strand break sites facilitates SWI/SNF chromatin remodeling and the recruitment of non-homologous end joining factors.
Oncogene. 30(18):2135-2146. 2011
doi: 10.1038/onc.2010.592. PMID: 21217779
Ogiwara H., and Kohno T.
Essential factors for incompatible DNA end joining at chromosomal DNA double strand breaks in vivo.
PLoS One. 6(12):e28756. 2011
doi: 10.1371/journal.pone.0028756. PMID: 22194904
Li S, Kanno S, Watanabe R, Ogiwara H, Kohno T, Watanabe G, Yasui A, Lieber MR.
Polynucleotide kinase and aprataxin-like forkhead-associated protein (PALF) acts as both a single-stranded DNA endonuclease and a single-stranded DNA 3' exonuclease and can participate in DNA end joining in a biochemical system.
J Biol Chem. 286(42):36368-36377. 2011
doi: 10.1074/jbc.M111.287797. PMID: 21885877
Lan L., Ui A., Nakajima S., Hatakeyama K., Hoshi M., Watanabe R., Janicki S. M., Ogiwara H., Kohno T., Kanno S., Yasui, A.
The ACF1 complex is required for DNA double-strand break repair in human cells.
Mol Cell. 40(6):976-987. 2010
doi: 10.1016/j.molcel.2010.12.003. PMID: 21172662
Kohno T., Otsuka A., Girard L., Sato M., Iwakawa R., Ogiwara H., Sanchez-Cespedes M., Minna J.D., Yokota J.
A catalog of genes homozygously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor gene.
Genes Chromosomes Cancer. 49(4):342-352. 2010
doi: 10.1002/gcc.20746. PMID: 20073072
Ogiwara H., Kohno T., Nakanishi H., Nagayama K., Sato M., Yokota J.
Unbalanced translocation, a major chromosome alteration causing loss of heterozygosity in human lung cancer.
Oncogene. 27(35):4788-4797. 2008
doi: 10.1038/onc.2008.113. PMID: 18408757
Ohuchi T, Seki M, Branzei D, Maeda D, Ui A, Ogiwara H, Tada S, Enomoto T.
Rad52 sumoylation and its involvement in the efficient induction of homologous recombination.
DNA Repair. 7:879-889. 2008
Ogiwara H., Ui A., Kawashima S., Kugou K., Onoda F., Iwahashi H., Harata M., Ohta K., Enomoto T., Seki M.
Actin-related protein Arp4 functions in kinetochore assembly.
Nucleic Acids Res. 35:3109-3117. 2007.
Ogiwara H., Ohuchi T., Ui A., Tada S., Enomoto T., Seki M.
Ctf18 is required for homologous recombination-mediated double-strand break repair.
Nucleic Acids Res. 35:4989-5000. 2007
Ogiwara H., Ui A., Enomoto T., Seki M.
Role of Elg1 protein in double strand break repair.
Nucleic Acids Res. 35:353-362. 2007
Ogiwara H., Enomoto T., Seki M.
The INO80 chromatin remodeling complex functions in sister chromatid cohesion.
Cell Cycle. 6(9):1090-1095. 2007
Ogiwara H., Ui A., Lai MS., Enomoto T., Seki M.
Chl1 and Ctf4 are required for damage-induced recombinations.
Biochem Biophys Res Commun. 354:222-226.2007
Tomizawa Y, Ui A, Onoda F, Ogiwara H, Tada S, Enomoto T, Seki M.
Rad50 is involved in MMS-induced recombination between homologous chromosomes in mitotic cells.
Genes Genet Syst. 82:157-160. 2007
Ui A, Seki M, Ogiwara H, Lai MS, Yamamoto K, Tada S, Enomoto T.
Activation of a novel pathway involving Mms1 and Rad59 in sgs1 cells.
Biochem Biophys Res Commun. 356:1031-1037. 2007
Kawashima S, Ogiwara H, Tada S, Harata M, Wintersberger U, Enomoto T, Seki M.
The INO80 complex is required for damage-induced recombination.
Biochem Biophys Res Commun. 355:835-841. 2007
Ogiwara H., Ui A., Onoda F., Tada S., Enomoto T., Seki M.
Dpb11, the budding yeast homolog of TopBP1, functions with the checkpoint clamp in recombination repair.
Nucleic Acids Res. 34:3389-3398.2006
Ui A, Seki M, Ogiwara H, Onodera R, Fukushige S, Onoda F, Enomoto T.
The ability of Sgs1 to interact with DNA topoisomerase III is essential for damage-induced recombination.
DNA Repair. 4(2):191-201. 2005
